interim marketing authorization regarding the use of the maltogenic amylase obtained from the genetically modified bacillus subtilis brg-1 pbrg-1 in starch used in the production of dextrins maltose dextrose glucose glucose syrup or glucose solids dried glucose syrup and in a variety of bakery products available in english and french pages 2103-2104 . provision currently exists in table v to section b.16.100 of the food and drug regulations for the use of the enzyme maltogenic amylase from bacillus subtilis dn1413 pdn1413 in the production of starch-derived sweetening agents and a variety of bakery products at levels consistent with good manufacturing practice. furthermore an interim marketing authorization ima was published in the canada gazette part i on 21 june 2003 g sps n can 177 notification g sps n can 206 replaces notification g sps n can 177. as such members are requested to consult g sps n can 206. to permit the immediate use of the maltogenic amylase from the genetically modified bacillus subtilis lfa63. the use of this enzyme was permitted for the same purposes as the other maltogenic amylase enzyme already listed in the regulations while the regulatory process was undertaken to amend the regulations. health canada has received a submission to permit the use of the maltogenic amylase enzyme obtained from a genetically modified bacillus subtilis micro-organism bacillus subtilis brg-1 pbrg-1 that carries the gene from bacillus stearothermophilus coding for this enzyme. evaluation of available data supports the safety and effectiveness of the maltogenic amylase from the genetically modified bacillus subtilis brg-1 pbrg-1 . therefore it is the intention of health canada to recommend that the food and drug regulations be amended to permit the use of the maltogenic amylase obtained from the genetically modified bacillus subtilis brg-1 pbrg-1 in starch used in the production of dextrins maltose dextrose glucose glucose syrup or glucose solids dried glucose syrup and in a variety of bakery products at levels consistent with good manufacturing practice. as a means to improve the responsiveness of the regulatory system an interim marketing authorization ima is being issued to permit the immediate use of the maltogenic amylase enzyme as indicated above while the regulatory process is undertaken to formally amend the regulations. a revision to this notification will be published at the start of the amendment process and members will be given the opportunity at that time to submit comments on this proposed measure